肝硬化患者增殖性肝细胞癌:LI-RADS 4/5类与M类的患者结局
回顾性多阅片者研究纳入204例肝硬化单发初治肝细胞癌(≤5.0 cm)患者,比较增殖性与非增殖性肝细胞癌中CT/MRI LR-4/5与LR-M的比例,并分析LI-RADS分类与病理分型对总生存期和无复发生存期的影响。结果显示增殖性肝细胞癌中LR-M比例显著更高,且CT/MRI LR-M与较差的总生存期和无复发生存期独立相关。
要点
- 增殖性肝细胞癌的CT LR-M比例为15.8%,高于非增殖性的3.0%(p=0.007)。
- 增殖性肝细胞癌的MRI LR-M比例为26.3%,高于非增殖性的9.6%(p=0.016)。
- CT/MRI LR-M与较差的总生存期和无复发生存期独立相关,不受病理分型影响。
核心结论
- 增殖性肝细胞癌中LR-M比例显著高于非增殖性肝细胞癌;CT/MRI LR-M与较差的总生存期和无复发生存期显著相关,且独立于增殖性与非增殖性病理分类。
研究设计与样本
- 回顾性多阅片者研究,纳入204例肝硬化单发初治肝细胞癌(≤5.0 cm)患者,接受增强CT、MRI及后续肝切除(2个月内)。
关键影像表现/征象
- CT上LR-M在增殖性肝细胞癌中占15.8%,在非增殖性中占3.0%(p=0.007)。
- MRI上LR-M在增殖性肝细胞癌中占26.3%,在非增殖性中占9.6%(p=0.016)。
诊断标准与关键数值
- 增殖性肝细胞癌中CT LR-M比例为15.8%,非增殖性为3.0%(p=0.007)。
- 增殖性肝细胞癌中MRI LR-M比例为26.3%,非增殖性为9.6%(p=0.016)。
- CT LR-M与LR-4/5相比,总生存期HR=4.58(p=0.013),无复发生存期HR=3.66(p=0.005)。
- MRI LR-M与LR-4/5相比,总生存期HR=6.45(p<0.001),无复发生存期HR=6.44(p<0.001)。
- 在增殖性和非增殖性肝细胞癌亚组中,MRI LR-M与MRI LR-4/5相比,总生存期(p≤0.003)和无复发生存期(p<0.001)均显著更差。
临床应用与阅片要点
- CT和MRI LI-RADS M类可能有助于预测增殖性和非增殖性肝细胞癌患者的不良结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: We aimed to compare Liver Imaging Reporting and Data System (LI-RADS) category 4/5 and category M (LR-M) of proliferative hepatocellular carcinomas (HCCs) in cirrhotic patients and evaluate their impacts on prognosis.
METHODS: This retrospective multi-reader study included cirrhotic patients with single treatment-naïve HCC ≤ 5.0 cm who underwent contrast-enhanced CT, MRI, and subsequent hepatic resection within 2 months. The percentages of CT/MRI LR-4/5 and LR-M in proliferative and non-proliferative HCCs were compared. Univariable and multivariable Cox proportional hazards regression analyses were performed to assess the association of LI-RADS categories (LR-4/5 vs. LR-M) and pathologic classification (proliferative vs. non-proliferative) with overall survival (OS) and recurrence-free survival (RFS). Subgroups of patients with proliferative and non-proliferative HCCs were analyzed to compare OS and RFS between LR-4/5 and LR-M.
RESULTS: Of the 204 included patients, 38 were classified as having proliferative HCC. The percentages of LR-M were higher in proliferative than non-proliferative HCC on both CT (15.8% vs. 3.0%, p = 0.007) and MRI (26.3% vs. 9.6%, p = 0.016). Independent of pathologic classification, CT and MRI LR-M were significantly associated with poorer OS (hazard ratio (HR) = 4.58, p = 0.013, and HR = 6.45, p < 0.001) and RFS (HR = 3.66, p = 0.005, and HR = 6.44, p < 0.001) than LR-4/5. MRI LR-M was associated with significantly poorer OS (p ≤ 0.003) and RFS (p < 0.001) than MRI LR-4/5 in both proliferative and non-proliferative HCCs.
CONCLUSIONS: This multi-reader study showed that the percentages of LR-M were significantly higher in proliferative than non-proliferative HCCs. CT/MRI LR-M was significantly associated with poor OS and RFS, independent of the pathologic classification of proliferative versus non-proliferative HCCs.
CLINICAL RELEVANCE STATEMENT: CT and MRI LI-RADS category M can be clinically useful in predicting poor outcomes in patients with proliferative and non-proliferative hepatocellular carcinomas.
KEY POINTS: • The percentages of LR-M tumors on both CT and MRI were significantly higher in proliferative than non-proliferative hepatocellular carcinomas. • Independent of pathologic classification, CT/MRI LR-M categories were correlated with poor overall survival and recurrence-free survival. • Patients with both proliferative and non-proliferative hepatocellular carcinomas categorized as MRI LR-M had significantly poorer overall survival and recurrence-free survival than those categorized as MRI LR-4/5.
引用
- Heo S, Kang HJ, Choi SH, et al. Proliferative hepatocellular carcinomas in cirrhosis: patient outcomes of LI-RADS category 4/5 and category M. Eur Radiol. 2023. PMID: 37848775. doi:10.1007/s00330-023-10305-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。